AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis

Loaeza-del-Castillo, Aurora; Paz-Pineda, Francisco; Oviedo-Cárdenas, Edgar; Sánchez-Ávila, Francisco; Vargas-Voráckóva, Florencia

doi:10.1016/s1665-2681(19)31836-8

Cited by 233 publications

(180 citation statements)

References 28 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…If the score is intermediate (between -1.455 and 0.676), there is indeterminate probability and these patients need to have liver biopsy for further assessment Fibrosis 4 index: Uses age, AST, ALT and platelet count [31] : Age (yr) × AST (U/L)/platelet (10 9 /L) × [ALT (U/L)] 1/2 If the score is < 1.30, there is low probability of advanced hepatic fibrosis (negative predictive value 90%), if the score is > 2.67, there is high probability of advanced hepatic fibrosis (positive predictive value 80%). If the score is intermediate (1.30 to 2.67), the possibility of having advanced hepatic fibrosis is indeterminate and liver biopsy is warranted APRI [32] : AST level (IU/L)/AST upper limit of normal (IU/ L)/[platelet count (10 9 /L)] × 100 = If the score is ≤ 0.5, there is low probability of hepatic fibrosis negative predictive value 83% and if the score is > 1.5, there is high probability (positive predictive value 68.4%) of hepatic fibrosis [33] . The intermediate score is indeterminate and liver biopsy should be done in those patients BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NAFLD: Non-alcoholic fatty liver disease; IFG: Impaired fasting blood glucose; APRI: AST platelet ratio index.…”

Section: Pharmacotherapymentioning

confidence: 99%

Non-alcoholic fatty liver disease in 2015

Ahmed¹

2015

WJH

174

134

View full text Add to dashboard Cite

There is worldwide epidemic of non-alcoholic fatty liver disease (NAFLD). NAFLD is a clinical entity related to metabolic syndrome. Majority of the patients are obese but the disease can affect non-obese individuals as well. Metabolic factors and genetics play important roles in the pathogenesis of this disorder. The spectrum of disorders included in NAFLD are benign macrovesicular hepatic steatosis, non-alcoholic steatohepatitis, hepatic fibrosis, cirrhosis of liver and hepatocellular carcinoma. Although the disease remains asymptomatic most of the time, it can slowly progress to end stage liver disease. It will be the most common indication of liver transplantation in the future. It is diagnosed by abnormal liver chemistry, imaging studies and liver biopsy. As there are risks of potential complications during liver biopsy, many patients do not opt for liver biopsy. There are some noninvasive scoring systems to find out whether patients have advanced hepatic fibrosis. At the present time, there are limited treatment options which include lifestyle modification to loose weight, vitamin E and thioglitazones. Different therapeutic agents are being investigated for optimal management of this entity. There are some studies done on incretin based therapies in patients with NAFLD. Other potential agents will be silent information regulator protein Sirtuin and antifibrotic monoclonal antibody Simtuzumab against lysyl oxidase like molecule 2. But they are still in the investigational phase.

show abstract

Section: Pharmacotherapymentioning

confidence: 99%

Non-alcoholic fatty liver disease in 2015

Ahmed¹

2015

WJH

174

134

View full text Add to dashboard Cite

show abstract

“…Aspartate aminotransferase (AST) to platelet ratio index (APRI), which is an indicator of liver dysfunction, was calculated by use of the formula [3][4][5]:…”

Section: Study Samplementioning

confidence: 99%

Clinical features of Vibrio vulnificus infections in the coastal areas of the Ariake Sea, Japan

Matsumoto

Ohshige

Fujita

et al. 2010

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

“…By the time a PN-patient has developed jaundice, there is a high likelihood of irreversible bridging fibrosis on liver biopsy [15]. In the adult population, many noninvasive measures of hepatic fibrosis have been developed for use in patients with known liver disease [16][17][18][19][20][21][22][23][24][25][26][27]. These tests allow progressive monitoring of liver disease with very low patient risk and have been shown to decrease rates of liver biopsies at centers where their use is routine.…”

mentioning

confidence: 99%